Trial Profile
Effect of Evolocumab on Coronary Endothelial Function
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Coronary artery disease
- Focus Biomarker; Therapeutic Use
- Acronyms EVOLVE
- 04 Dec 2019 Status changed from recruiting to completed.
- 20 May 2019 Planned End Date changed from 1 Apr 2019 to 30 Nov 2019.
- 20 May 2019 Planned primary completion date changed from 1 Apr 2019 to 30 Nov 2019.